In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4. The company’s shares opened today at $1.95, close to its 52-week low of $1.80.
Livnat observed:
“Helm With Wind in Belbuca’s Sails; Reiterate Buy Stock Data 05/04/2018 Price $1.93 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.85 Enterprise Value (M) $146.4 Market Cap (M) $108 Shares Outstanding (M) 55.9 3 Month Avg Volume 373,600 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAY-17 SEP-17 JAN-18 MAY-18 3 2.5 2 1.5 1 0.5 0 Vol. (mil) Price New CEO finally announced. BDSI announced the appointment of new CEO, Herm Cukier, ahead 1Q18 results reporting Thursday, May 10. Mr.”
According to TipRanks.com, Livnat is ranked 0 out of 5 stars with an average return of -11.3% and a 26.5% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on BioDelivery is Moderate Buy and the average price target is $4.25, representing an 117.9% upside.
In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $4.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.60 and a one-year low of $1.80. Currently, BioDelivery has an average volume of 357K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.
